Here's Why Select Medical (SEM) is a Strong Momentum Stock

Select Medical (SEM) is highlighted as a strong momentum stock, despite its Zacks #3 (Hold) Rank, due to its 'A' VGM Score and 'B' Momentum Score. The healthcare provider has seen its shares rise 3.5% over the past four weeks, supported by upward revisions to its FY2025 earnings estimate by $0.03 to $1.17 per share within 60 days, and a historical average earnings surprise of 11.4%.

Analysis

Select Medical (SEM) is presented with a compelling momentum profile despite its neutral Zacks #3 (Hold) rating. The stock's attractiveness is underpinned by a top-tier 'A' for its composite VGM Score and a 'B' for its Momentum Style Score, which is supported by tangible data. Specifically, the company's shares have appreciated 3.5% over the past four weeks, demonstrating positive price momentum. This is complemented by positive earnings estimate momentum, as two analysts have revised their fiscal 2025 earnings forecasts upward within the last 60 days. These revisions have collectively lifted the Zacks Consensus Estimate for FY2025 by $0.03 to $1.17 per share. Furthermore, SEM has a track record of outperformance, boasting an average positive earnings surprise of 11.4%. The combination of recent price strength and upwardly revised earnings outlook forms the basis for the strong momentum designation, positioning the stock as noteworthy for investors focused on this factor, even while its broader 'Hold' rating suggests a more balanced overall view from the rating provider.

Key Decisions for Investors

• Momentum-focused investors should consider SEM for their watchlist, given the favorable combination of a 'B' Momentum Score, recent 3.5% price increase, and upward revisions to FY2025 earnings estimates.
• Investors should weigh the positive momentum indicators against the neutral Zacks #3 (Hold) rank, which may imply that valuation or other fundamental factors could temper the longer-term outlook.
• Monitor the trend in analyst earnings estimates for FY2025, as continued upward revisions are a critical pillar supporting the current momentum thesis for the stock.